ResearchMoz.us include new market research report " Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018" to its huge collection of research reports. Norway In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018 provides key market data on the Norway In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Directs team of industry experts.
Scope
- Market size and company share data for In Vitro Diagnostics market categories Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the Norway In Vitro Diagnosticsmarket.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Ortho-Clinical Diagnostics Inc., bioMerieux S.A., Beckman Coulter, Inc. and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Norway In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and whats the most preferred mode of product distribution Identify, understand and capitalize.
For More Information, Please Visit@ Norway In Vitro Diagnostics Investment
Table Of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
8 Immuno Chemistry In Norway 76
8.1 Immuno Chemistry Overall Revenue, (2004-2018) 76
8.1.1 Disease Specific Immunochemistry, Revenue (2004-2018) 80
8.1.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 84
8.1.3 Endocrinology Tests, Revenue (2004-2018) 88
8.1.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 92
8.1.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 96
8.1.6 Immunochemistry Analyzers, Revenue (2004-2018) 100
8.2 Immuno Chemistry Distribution Share (2010-2011) 104
8.3 Immuno Chemistry, Norway, Company Share (2010-2011) 105
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Introduction 112.1 What is This Report About? 11
3 In Vitro Diagnostics In Norway 12
3.1 In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018 12
3.2 In Vitro Diagnostics, Norway, Company Share (2010-2011) 18
3.1 In Vitro Diagnostics, Norway, Overall Revenue ($m) , USD Constant, 2004-2018 12
3.2 In Vitro Diagnostics, Norway, Company Share (2010-2011) 18
4 Clinical Chemistry In Norway 20
4.1 Clinical Chemistry Overall Revenue, (2004-2018) 20
4.1.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 24
4.1.2 Urine Analysis, Revenue (2004-2018) 28
4.2 Clinical Chemistry Distribution Share (2010-2011) 32
4.3 Clinical Chemistry, Norway, Company Share (2010-2011) 33
4.1 Clinical Chemistry Overall Revenue, (2004-2018) 20
4.1.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 24
4.1.2 Urine Analysis, Revenue (2004-2018) 28
4.2 Clinical Chemistry Distribution Share (2010-2011) 32
4.3 Clinical Chemistry, Norway, Company Share (2010-2011) 33
5 Genetic Testing In Norway 355.1 Genetic Testing Overall Revenue, (2004-2018) 35
5.2 Genetic Testing Distribution Share (2010-2011) 39
5.3 Genetic Testing, Norway, Company Share (2010-2011) 40
5.2 Genetic Testing Distribution Share (2010-2011) 39
5.3 Genetic Testing, Norway, Company Share (2010-2011) 40
6 Haematology In Norway 42
6.1 Haematology Overall Revenue, (2004-2018) 42
6.1.1 Haematology Reagents, Revenue , (2004-2018) 46
6.1.2 Immunohaematology, Revenue (2004-2018) 50
6.1.3 Haemostasis, Revenue (2004-2018) 54
6.1.4 Haematology Rapid Tests, Revenue (2004-2018) 58
6.1.5 Haematology Cell Counters, Revenue (2004-2018) 62
6.2 Haematology Distribution Share (2010-2011) 66
6.3 Haematology, Norway, Company Share (2010-2011) 67
6.1 Haematology Overall Revenue, (2004-2018) 42
6.1.1 Haematology Reagents, Revenue , (2004-2018) 46
6.1.2 Immunohaematology, Revenue (2004-2018) 50
6.1.3 Haemostasis, Revenue (2004-2018) 54
6.1.4 Haematology Rapid Tests, Revenue (2004-2018) 58
6.1.5 Haematology Cell Counters, Revenue (2004-2018) 62
6.2 Haematology Distribution Share (2010-2011) 66
6.3 Haematology, Norway, Company Share (2010-2011) 67
7 Histology And Cytology In Norway 697.1 Histology And Cytology Overall Revenue, (2004-2018) 69
7.2 Histology And Cytology Distribution Share (2010-2011) 73
7.3 Histology And Cytology, Norway, Company Share (2010-2011) 74
7.2 Histology And Cytology Distribution Share (2010-2011) 73
7.3 Histology And Cytology, Norway, Company Share (2010-2011) 74
8 Immuno Chemistry In Norway 76
8.1 Immuno Chemistry Overall Revenue, (2004-2018) 76
8.1.1 Disease Specific Immunochemistry, Revenue (2004-2018) 80
8.1.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 84
8.1.3 Endocrinology Tests, Revenue (2004-2018) 88
8.1.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 92
8.1.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 96
8.1.6 Immunochemistry Analyzers, Revenue (2004-2018) 100
8.2 Immuno Chemistry Distribution Share (2010-2011) 104
8.3 Immuno Chemistry, Norway, Company Share (2010-2011) 105
9 Infectious Immunology In Norway 107
9.1 Infectious Immunology Overall Revenue, (2004-2018) 107
9.1.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 111
9.2 Infectious Immunology Distribution Share (2010-2011) 115
9.3 Infectious Immunology, Norway, Company Share (2010-2011) 116
9.1 Infectious Immunology Overall Revenue, (2004-2018) 107
9.1.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 111
9.2 Infectious Immunology Distribution Share (2010-2011) 115
9.3 Infectious Immunology, Norway, Company Share (2010-2011) 116
View Full Report, Kindly Visit@ http://www.researchmoz.us/norway-in-vitro-diagnostics-investment-opportunities-analysis-and-forecasts-to-2018-report.html
10 Microbiology Culture In Norway 118
10.1 Microbiology Culture Overall Revenue, (2004-2018) 118
10.1.1 Microbiology Analyzers, Revenue (2004-2018) 122
10.2 Microbiology Culture Distribution Share (2010-2011) 126
10.3 Microbiology Culture, Norway, Company Share (2010-2011) 127
10.1 Microbiology Culture Overall Revenue, (2004-2018) 118
10.1.1 Microbiology Analyzers, Revenue (2004-2018) 122
10.2 Microbiology Culture Distribution Share (2010-2011) 126
10.3 Microbiology Culture, Norway, Company Share (2010-2011) 127
11 Overview of Key Companies in Norway In Vitro Diagnostics Market 129
11.1 F. Hoffmann-La Roche Ltd. 129
11.1.1 Company Overview 129
11.2 Siemens Healthcare 129
11.2.1 Company Overview 129
11.3 Abbott Laboratories 129
11.3.1 Company Overview 129
11.4 Ortho-Clinical Diagnostics Inc. 130
11.4.1 Company Overview 130
11.5 bioMerieux S.A. 130
11.5.1 Company Overview 130
11.6 Beckman Coulter, Inc. 131
11.6.1 Company Overview 131
11.7 Sysmex Corporation 131
11.7.1 Company Overview 131
11.8 Bio-Rad Laboratories, Inc. 131
11.8.1 Company Overview 131
11.9 Becton, Dickinson and Company 132
11.9.1 Company Overview 132
11.10 Alere Inc. 132
11.10.1 Company Overview 132
11.11 Mindray Medical International Limited 133
11.11.1 Company Overview 133
11.12 Danaher Corporation 133
11.12.1 Company Overview 133
11.13 Qiagen N.V. 134
11.13.1 Company Overview 134
11.14 DiaSorin S.p.A 134
11.14.1 Company Overview 134
11.15 Diagnostica Stago, Inc. 135
11.15.1 Company Overview 135
11.16 Thermo Fisher Scientific Inc. 135
11.16.1 Company Overview 135
11.17 PerkinElmer, Inc. 136
11.17.1 Company Overview 136
11.18 Horiba, Ltd. 136
11.18.1 Company Overview 136
11.19 Gen-Probe Incorporated 137
11.19.1 Company Overview 137
11.20 Immucor, Inc. 137
11.20.1 Company Overview 137
11.21 Life Technologies Corporation 138
11.21.1 Company Overview 138
11.22 Grifols, S.A. 138
11.22.1 Company Overview 138
11.23 Cellestis Limited 139
11.23.1 Company Overview 139
11.24 Hologic, Inc. 139
11.24.1 Company Overview 139
11.1 F. Hoffmann-La Roche Ltd. 129
11.1.1 Company Overview 129
11.2 Siemens Healthcare 129
11.2.1 Company Overview 129
11.3 Abbott Laboratories 129
11.3.1 Company Overview 129
11.4 Ortho-Clinical Diagnostics Inc. 130
11.4.1 Company Overview 130
11.5 bioMerieux S.A. 130
11.5.1 Company Overview 130
11.6 Beckman Coulter, Inc. 131
11.6.1 Company Overview 131
11.7 Sysmex Corporation 131
11.7.1 Company Overview 131
11.8 Bio-Rad Laboratories, Inc. 131
11.8.1 Company Overview 131
11.9 Becton, Dickinson and Company 132
11.9.1 Company Overview 132
11.10 Alere Inc. 132
11.10.1 Company Overview 132
11.11 Mindray Medical International Limited 133
11.11.1 Company Overview 133
11.12 Danaher Corporation 133
11.12.1 Company Overview 133
11.13 Qiagen N.V. 134
11.13.1 Company Overview 134
11.14 DiaSorin S.p.A 134
11.14.1 Company Overview 134
11.15 Diagnostica Stago, Inc. 135
11.15.1 Company Overview 135
11.16 Thermo Fisher Scientific Inc. 135
11.16.1 Company Overview 135
11.17 PerkinElmer, Inc. 136
11.17.1 Company Overview 136
11.18 Horiba, Ltd. 136
11.18.1 Company Overview 136
11.19 Gen-Probe Incorporated 137
11.19.1 Company Overview 137
11.20 Immucor, Inc. 137
11.20.1 Company Overview 137
11.21 Life Technologies Corporation 138
11.21.1 Company Overview 138
11.22 Grifols, S.A. 138
11.22.1 Company Overview 138
11.23 Cellestis Limited 139
11.23.1 Company Overview 139
11.24 Hologic, Inc. 139
11.24.1 Company Overview 139
12 Appendix 140
12.1 Global Markets Direct Research Methodology 140
12.2 Definitions of Markets Covered in the Report 141
12.2.1 In Vitro Diagnostics 141
12.3 Secondary Research 152
12.4 Primary Research 152
12.5 Models 153
12.6 Forecasts 153
12.7 Expert Panel Validation 153
12.8 Currency Conversion 154
12.9 Contact Us 154
12.10 Disclaimer 154
12.1 Global Markets Direct Research Methodology 140
12.2 Definitions of Markets Covered in the Report 141
12.2.1 In Vitro Diagnostics 141
12.3 Secondary Research 152
12.4 Primary Research 152
12.5 Models 153
12.6 Forecasts 153
12.7 Expert Panel Validation 153
12.8 Currency Conversion 154
12.9 Contact Us 154
12.10 Disclaimer 154
To know more about this reports, please visit @ http://www.researchmoz.us/norway-in-vitro-diagnostics-investment-opportunities-analysis-and-forecasts-to-2018-report.html
See All Latest Market Research Reports@ http://www.researchmoz.us/report.html
Contact: sales@researchmoz.us for further information.
Find us on:
No comments:
Post a Comment